Cureveda is focused on developing drugs for the treatment of respiratory diseases, particularly COPD.
Patients with COPD suffer from chronic bronchitis, emphysema or both and show progressive decline in lung function as described by Gold stages ( I (mild), II (moderate), III – IV (severe)).
Patients with COPD also develop other co-morbid conditions such as skeletal muscle wasting and cachexia, cardiovascular and metabolic. COPD is the third leading cause of mortality in the United States. The World Health Organization estimated that more than 210 million people worldwide are affected by COPD and also estimates that total deaths from COPD are projected to increase by more than 30% in the next 10 years and will be the third leading cause of death by 2030.
Current treatment options provide symptomatic management of COPD but none of them halt or retard the progression of COPD. Biological processes that have been implicated in development of COPD are protease-anti-protease imbalance, oxidant-antioxidant imbalance, excessive inflammation and susceptibility to recurrent viral and bacterial infections.
Cureveda will apply the current “knowledge map” to develop drugs targeting pathways that will inhibit these biological processes involved in the progression of disease.